8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 13, 2026·SEC
Material company update
Mar 12, 2026·SEC
The Oncology Institute, Inc.(TOI)Earnings, Financials & Key Ratios
TOI•NASDAQ
Price updated Jun 13, 2026
AboutThe Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.Show more
- Revenue$503M+27.8%
- EBITDA-$29M+45.9%
- Net Income-$61M+6.3%
- EPS (Diluted)-0.54+23.9%
- Gross Margin15.2%+10.8%
- EBITDA Margin-5.8%+57.6%
- Operating Margin-7.18%+53.0%
- Net Margin-12.06%+26.7%
- ROIC-41.17%-0.6%
- Interest Coverage-4.39+45.3%
TOI Key Insights
The Oncology Institute, Inc. (TOI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Strong 5Y sales CAGR of 21.8%
- ✓Trading near 52-week high
- ✓Efficient asset utilization: 3.1x turnover
✗Weaknesses
- ✗Profits declining 33.4% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TOI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TOI Price & Volume
The Oncology Institute, Inc. (TOI) stock price & volume — 10-year historical chart
Loading chart...
TOI Growth Metrics
The Oncology Institute, Inc. (TOI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years21.8%
3 Years25.81%
TTM35.37%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM32.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM50%
Return on Capital
10 Years-31.69%
5 Years-39.26%
3 Years-37.45%
Last Year-33.69%
TOI Recent Earnings
The Oncology Institute, Inc. (TOI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (18%)●Beat Revenue 4/12 qtrs (36%)
Q2 2026Latest
May 7, 2026EPS
$0.02
Est $0.07
+71.4%
Revenue
$147M
Est $142M
+3.8%
Q2 2026
Mar 12, 2026EPS
$0.06
Est $0.08
+25.0%
Revenue
$142M
Est $140M
+1.6%
Q4 2025
Nov 13, 2025EPS
$0.14
Est $0.12
-16.7%
Revenue
$137M
Est $140M
-2.3%
Q3 2025
Aug 13, 2025EPS
$0.14
Est $0.14
+0.0%
Revenue
$120M
Est $123M
-2.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.02vs $0.07+71.4% | $147Mvs $142M+3.8% |
| Q2 2026 | Mar 12, 2026 | $0.06vs $0.08+25.0% | $142Mvs $140M+1.6% |
| Q4 2025 | Nov 13, 2025 | $0.14vs $0.12-16.7% | $137Mvs $140M-2.3% |
| Q3 2025 | Aug 13, 2025 | $0.14vs $0.14+0.0% | $120Mvs $123M-2.2% |
Based on last 12 quarters of dataView full earnings history →
TOI Peer Comparison
The Oncology Institute, Inc. (TOI) competitors in Specialty chronic care clinics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AIOT | 574.36M | 4.22 | -9.81 | -7.4% | -6.64% | 0.64 | ||
 ONCO | 653.67K | 1.04 | -0.22 | -67.7% | -13.2% | -105.46% | 0.00 | |
 USPH | 998.5M | 65.56 | 46.17 | 16.33% | 1.52% | 1.36% | 0.55 | |
 OPCH | 3.25B | 20.76 | 16.35 | 13.03% | 3.64% | 15.28% | ||
 ADUS | 1.74B | 93.28 | 17.90 | 23.21% | 6.89% | 9.34% | 0.19 | |
 AMSF | 592.6M | 31.53 | 12.77 | 2.63% | 14.27% | 9.68% | 0.00 | |
 MCK | 94.25B | 784.05 | 20.43 | 12.36% | 1.18% | |||
 CAH | 52.68B | 223.85 | 34.71 | -1.87% | 0.62% |
Compare TOI vs Peers
The Oncology Institute, Inc. (TOI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TOI Income Statement
The Oncology Institute, Inc. (TOI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 155.41M | 187.51M | 203M | 252.48M | 324.24M | 393.41M | 502.73M | 545.76M |
Revenue Growth % | - | 20.66% | 8.26% | 24.37% | 28.42% | 21.33% | 27.79% | 35.37% |
Cost of Goods Sold | 125.46M | 150.64M | 162.16M | 200.39M | 264.67M | 339.42M | 426.29M | 464.88M |
COGS % of Revenue | 80.73% | 80.33% | 79.88% | 79.37% | 81.63% | 86.27% | 84.8% | - |
Gross Profit | 29.94M▲ 0% | 36.88M▲ 23.2% | 40.85M▲ 10.8% | 52.09M▲ 27.5% | 59.57M▲ 14.4% | 54M▼ 9.4% | 76.44M▲ 41.6% | 80.89M▲ 0% |
Gross Margin % | 19.27% | 19.67% | 20.12% | 20.63% | 18.37% | 13.73% | 15.2% | 14.82% |
Gross Profit Growth % | - | 23.17% | 10.76% | 27.53% | 14.36% | -9.36% | 41.55% | - |
Operating Expenses | 32.59M | 45.07M | 86.71M | 134.04M | 136.59M | 114.11M | 112.52M | 113.57M |
OpEx % of Revenue | 20.97% | 24.04% | 42.71% | 53.09% | 42.13% | 29.01% | 22.38% | - |
Selling, General & Admin | 29.64M | 41.9M | 0 | 0 | 0 | 0 | 105.57M | 81.5M |
SG&A % of Revenue | 19.07% | 22.34% | - | - | - | - | 21% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - |
Other Operating Expenses | 2.94M | 3.18M | 86.71M | 134.04M | 136.59M | 114.11M | 6.94M | 3M |
Operating Income | -2.64M▲ 0% | -8.2M▼ 209.9% | -45.86M▼ 459.5% | -81.95M▼ 78.7% | -77.02M▲ 6.0% | -60.12M▲ 21.9% | -36.08M▲ 40.0% | -32.69M▲ 0% |
Operating Margin % | -1.7% | -4.37% | -22.59% | -32.46% | -23.75% | -15.28% | -7.18% | -5.99% |
Operating Income Growth % | - | -209.89% | -459.52% | -78.71% | 6.02% | 21.94% | 39.98% | - |
EBITDA | 297.11K | -5.02M | -42.52M | -77.54M | -71.14M | -53.83M | -29.14M | -25.91M |
EBITDA Margin % | 0.19% | -2.68% | -20.94% | -30.71% | -21.94% | -13.68% | -5.8% | -4.75% |
EBITDA Growth % | - | -1788.91% | -747.31% | -82.37% | 8.25% | 24.34% | 45.87% | 43.03% |
D&A (Non-Cash Add-back) | 2.94M | 3.18M | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M | 6.78M |
EBIT | -2.63M | -14.47M | -45.38M | -72.01M | -60.15M | -60.12M | -49.46M | -37.9M |
Net Interest Income | -3.38K | -347K | -320K | -4.08M | -6.78M | -7.5M | -11.28M | -7.64M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 3.38K | 347K | 320K | 4.08M | 6.78M | 7.5M | 11.28M | 7.64M |
Other Income/Expense | 6.63K | -6.62M | 34.26M | 81.86M | -6.09M | -4.54M | -24.65M | -10.96M |
Pretax Income | -2.64M▲ 0% | -14.81M▼ 461.5% | -11.6M▲ 21.7% | -91K▲ 99.2% | -83.1M▼ 91223.1% | -64.66M▲ 22.2% | -60.74M▲ 6.1% | -43.64M▲ 0% |
Pretax Margin % | -1.7% | -7.9% | -5.71% | -0.04% | -25.63% | -16.44% | -12.08% | -8% |
Income Tax | 1.38M | -492.82K | -671K | -243K | -36K | 0 | -131K | -131K |
Effective Tax Rate % | -52.43% | 3.33% | 5.79% | 267.03% | 0.04% | 0% | 0.22% | 0.3% |
Net Income | -4.02M▲ 0% | -14.32M▼ 256.1% | -10.93M▲ 23.7% | 152K▲ 101.4% | -83.07M▼ 54750.0% | -64.66M▲ 22.2% | -60.61M▲ 6.3% | -43.51M▲ 0% |
Net Margin % | -2.59% | -7.64% | -5.38% | 0.06% | -25.62% | -16.44% | -12.06% | -7.97% |
Net Income Growth % | - | -256.13% | 23.7% | 101.39% | -54750% | 22.16% | 6.27% | 32.39% |
Net Income (Continuing) | -4.02M | -14.32M | -10.93M | 152K | -83.07M | -64.66M | -60.61M | -43.51M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.06▲ 0% | -0.24▼ 284.6% | -0.16▲ 33.3% | -0.21▼ 31.2% | -0.92▼ 338.1% | -0.71▲ 22.8% | -0.54▲ 23.9% | -0.04▲ 0% |
EPS Growth % | - | -284.62% | 33.33% | -31.25% | -338.1% | 22.83% | 23.94% | 50% |
EPS (Basic) | -0.06 | -0.24 | -0.16 | 0.00 | -0.92 | -0.71 | -0.54 | - |
Diluted Shares Outstanding | 64.45M | 59.12M | 66.23M | 80.61M | 73.75M | 75.04M | 923.89M | 1.02B |
Basic Shares Outstanding | 64.45M | 59.12M | 66.23M | 72.79M | 73.75M | 75.04M | 923.89M | 1.02B |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TOI Balance Sheet
The Oncology Institute, Inc. (TOI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 21.79M | 29.72M | 154.06M | 130.42M | 143.49M | 112.42M | 112.75M | 116.86M |
Cash & Short-Term Investments | 2.45M | 6M | 114.3M | 73.81M | 82.86M | 49.67M | 33.56M | 30.28M |
Cash Only | 2.45M | 6M | 114.3M | 14.01M | 33.49M | 49.67M | 33.56M | 30.28M |
Short-Term Investments | 0 | 0 | 0 | 59.8M | 49.37M | 0 | 0 | 0 |
Accounts Receivable | 14.73M | 17.26M | 21.24M | 40.43M | 42.91M | 48.68M | 59.32M | 59.45M |
Days Sales Outstanding | 34.61 | 33.59 | 38.2 | 58.45 | 48.31 | 45.17 | 43.07 | 39.19 |
Inventory | 3.89M | 4.35M | 6.44M | 9.26M | 13.68M | 10.04M | 16.88M | 24.29M |
Days Inventory Outstanding | 11.31 | 10.55 | 14.49 | 16.87 | 18.86 | 10.8 | 14.45 | 14.89 |
Other Current Assets | 0 | 0 | 875K | 0 | 0 | 4.03M | 2.99M | 2.84M |
Total Non-Current Assets | 37.73M | 35.97M | 49.38M | 131.25M | 65.75M | 60.3M | 51.91M | 51.37M |
Property, Plant & Equipment | 1.55M | 2.1M | 4.19M | 33.04M | 40.05M | 37.67M | 33.06M | 33.22M |
Fixed Asset Turnover | 100.20x | 89.12x | 48.43x | 7.64x | 8.10x | 10.44x | 15.21x | 16.17x |
Goodwill | 14.08M | 14.23M | 26.63M | 21.42M | 7.23M | 7.23M | 7.23M | 7.23M |
Intangible Assets | 22M | 19.52M | 18.25M | 17.96M | 17.9M | 14.81M | 11.02M | 10.3M |
Long-Term Investments | 0 | 0 | -371K | 58.35M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 97.85K | 122K | 320K | 477K | 561K | 589K | 606K | 620K |
Total Assets | 59.52M▲ 0% | 65.69M▲ 10.4% | 203.44M▲ 209.7% | 261.67M▲ 28.6% | 209.24M▼ 20.0% | 172.72M▼ 17.5% | 164.66M▼ 4.7% | 168.23M▲ 0% |
Asset Turnover | 2.61x | 2.85x | 1.00x | 0.96x | 1.55x | 2.28x | 3.05x | 3.33x |
Asset Growth % | - | 10.36% | 209.7% | 28.62% | -20.04% | -17.46% | -4.67% | -21.8% |
Total Current Liabilities | 13.59M | 28.61M | 29.8M | 29.72M | 34.79M | 52.22M | 70.96M | 79.35M |
Accounts Payable | 8.89M | 12.64M | 15.56M | 9.37M | 14.43M | 24.32M | 43.17M | 47.65M |
Days Payables Outstanding | 25.85 | 30.63 | 35.02 | 17.07 | 19.9 | 26.16 | 36.96 | 31.68 |
Short-Term Debt | 0 | 5.37M | 183K | 0 | 0 | 0 | 0 | 7.4M |
Deferred Revenue (Current) | 0 | 3.38M | 592K | 1.14M | 545K | 4.7M | 2.28M | 0 |
Other Current Liabilities | 0 | -3.38M | 10.14M | 9.35M | 11.32M | 10.35M | 13.15M | 24.3M |
Current Ratio | 1.60x | 1.04x | 5.17x | 4.39x | 4.12x | 2.15x | 1.59x | 1.47x |
Quick Ratio | 1.32x | 0.89x | 4.95x | 4.08x | 3.73x | 1.96x | 1.35x | 1.17x |
Cash Conversion Cycle | 20.07 | 13.51 | 17.67 | 58.25 | 47.27 | 29.8 | 20.56 | 22.4 |
Total Non-Current Liabilities | 3.71M | 8.98M | 69.48M | 108.77M | 117.43M | 116.91M | 109.41M | 105.16M |
Long-Term Debt | 0 | 6.56M | 0 | 80.62M | 86.83M | 93.13M | 77.4M | 18.84M |
Capital Lease Obligations | 0 | 0 | 0 | 22.06M | 26.49M | 23.22M | 19.13M | 21.23M |
Deferred Tax Liabilities | 2.96M | 1.61M | 371K | 108K | 32K | 32K | 0 | 0 |
Other Non-Current Liabilities | 756.42K | 807K | 69.11M | 5.98M | 4.08M | 527K | 12.88M | 86.32M |
Total Liabilities | 17.3M | 37.59M | 99.28M | 138.49M | 152.22M | 169.13M | 180.38M | 184.51M |
Total Debt | 0 | 11.93M | 183K | 108.18M | 119.67M | 123.15M | 103.69M | 26.25M |
Net Debt | -2.45M | 5.93M | -114.12M | 94.17M | 86.19M | 73.48M | 70.12M | -4.03M |
Debt / Equity | - | 0.42x | 0.00x | 0.88x | 2.10x | 34.31x | - | -1.61x |
Debt / EBITDA | - | - | - | - | - | - | - | -1.01x |
Net Debt / EBITDA | -8.23x | - | - | - | - | - | - | 0.16x |
Interest Coverage | -780.67x | -41.69x | -141.82x | -17.64x | -8.88x | -8.02x | -4.39x | -4.96x |
Total Equity | 42.22M▲ 0% | 28.1M▼ 33.4% | 104.16M▲ 270.7% | 123.17M▲ 18.3% | 57.02M▼ 53.7% | 3.59M▼ 93.7% | -15.72M▼ 538.0% | -16.29M▲ 0% |
Equity Growth % | - | -33.45% | 270.66% | 18.26% | -53.7% | -93.71% | -538% | -1269.31% |
Book Value per Share | 0.66 | 0.48 | 1.57 | 1.53 | 0.77 | 0.05 | -0.02 | -0.02 |
Total Shareholders' Equity | 42.22M | 28.1M | 104.16M | 123.17M | 57.02M | 3.59M | -15.72M | -16.29M |
Common Stock | 0 | 6K | 7K | 7K | 8K | 8K | 10K | 10K |
Retained Earnings | -6.02M | -52.31M | -63.23M | -63.08M | -146.15M | -210.81M | -271.42M | -273.91M |
Treasury Stock | 0 | 0 | 0 | 0 | -1.02M | -1.02M | -1.02M | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TOI Cash Flow Statement
The Oncology Institute, Inc. (TOI) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | 3.62M | 508K | -32.68M | -61.76M | -36.31M | -26.54M | -24.59M | -21.81M |
Operating CF Margin % | 2.33% | 0.27% | -16.1% | -24.46% | -11.2% | -6.75% | -4.89% | - |
Operating CF Growth % | - | -85.95% | -6533.07% | -88.97% | 41.2% | 26.92% | 7.35% | -1574.44% |
Net Income | -4.02M | -14.32M | -10.93M | 152K | -83.07M | -53.01M | -60.61M | -43.51M |
Depreciation & Amortization | 2.94M | 3.18M | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M | 3.25M |
Stock-Based Compensation | 94.01K | 151K | 24.54M | 27.68M | 17.81M | 0 | 4.55M | 1.82M |
Deferred Taxes | 824.76K | -1.34M | -1.24M | -263K | -76K | 0 | -32K | 0 |
Other Non-Cash Items | 326.93K | 11.85M | -33.9M | -73.2M | 20.79M | 2.12M | 23.23M | -21.73M |
Working Capital Changes | 3.45M | 992K | -14.49M | -20.54M | 2.36M | 18.06M | 1.32M | -876K |
Change in Receivables | -4.44M | -6.76M | -2.99M | -19.66M | -4.5M | -5.77M | -12.58M | -11.73M |
Change in Inventory | -1.13M | -465K | -1.84M | -1.73M | -4.38M | 3.64M | -6.84M | -11.98M |
Change in Payables | 5.53M | 3.76M | 2.92M | -6.19M | 5.06M | 9.21M | 19.64M | 19.19M |
Cash from Investing | -1.2M | -8.84M | -12.15M | -131.61M | 62.64M | 46.21M | -3.07M | -3.91M |
Capital Expenditures | -1.2M | -1.19M | -2.85M | -5.53M | -4.57M | -3.79M | -3.2M | -2.71M |
CapEx % of Revenue | 0.78% | 0.64% | 1.4% | 2.19% | 1.41% | 0.96% | 0.64% | 0.5% |
Acquisitions | 0 | -150K | -9.11M | -8.58M | -4.46M | 0 | 0 | -126K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | -7.5M | -200K | 0 | 0 | 0 | 0 | -1.08M |
Cash from Financing | -1.81K | 11.89M | 154.01M | 92.21M | -6.85M | -3.49M | 11.56M | 16.27M |
Debt Issued (Net) | -1.81K | 12.18M | -7.25M | 109.94M | -101K | -39K | -20.04M | -36K |
Equity Issued (Net) | 0 | 0 | 20M | -9M | -1.02M | 75K | 32.63M | 16.49M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -9M | -1.02M | 0 | 0 | 0 |
Other Financing | 0 | -293K | 141.26M | -8.74M | -5.73M | -3.53M | -1.04M | -184K |
Net Change in Cash | 2.41M▲ 0% | 3.55M▲ 47.5% | 109.18M▲ 2973.6% | -101.16M▼ 192.7% | 19.48M▲ 119.3% | 16.18M▼ 16.9% | -16.1M▼ 199.5% | -9.46M▲ 0% |
Free Cash Flow | 2.41M▲ 0% | -686K▼ 128.5% | -35.73M▼ 5108.0% | -67.28M▼ 88.3% | -40.88M▲ 39.2% | -30.33M▲ 25.8% | -27.79M▲ 8.4% | -25.73M▲ 0% |
FCF Margin % | 1.55% | -0.37% | -17.6% | -26.65% | -12.61% | -7.71% | -5.53% | -4.71% |
FCF Growth % | - | -128.46% | -5108.02% | -88.33% | 39.24% | 25.82% | 8.38% | -34.35% |
FCF per Share | 0.04 | -0.01 | -0.54 | -0.83 | -0.55 | -0.40 | -0.03 | -0.03 |
FCF Conversion (FCF/Net Income) | -0.90x | -0.04x | 2.99x | -406.29x | 0.44x | 0.41x | 0.41x | 0.59x |
Interest Paid | 3.38K | 227K | 275K | 224K | 4.51M | 0 | 0 | 878K |
Taxes Paid | 61.27K | 207K | 1.73M | 150K | 403K | 0 | 0 | 0 |
TOI Key Ratios
The Oncology Institute, Inc. (TOI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -40.73% | -16.52% | 0.13% | -92.2% | -213.36% | - | 326.77% |
| Return on Invested Capital (ROIC) | -16.66% | -285.72% | -59.27% | -32.04% | -40.94% | -41.17% | -1169.83% |
| Gross Margin | 19.67% | 20.12% | 20.63% | 18.37% | 13.73% | 15.2% | 14.82% |
| Net Margin | -7.64% | -5.38% | 0.06% | -25.62% | -16.44% | -12.06% | -7.97% |
| Debt / Equity | 0.42x | 0.00x | 0.88x | 2.10x | 34.31x | - | -1.61x |
| Interest Coverage | -41.69x | -141.82x | -17.64x | -8.88x | -8.02x | -4.39x | -4.96x |
| FCF Conversion | -0.04x | 2.99x | -406.29x | 0.44x | 0.41x | 0.41x | 0.59x |
| Revenue Growth | 20.66% | 8.26% | 24.37% | 28.42% | 21.33% | 27.79% | 35.37% |
Related:TOI Dividend History·TOI Revenue History·TOI Price History·TOI P/E History·TOI Financial Ratios·TOI Institutional Holders
TOI SEC Filings & Documents
The Oncology Institute, Inc. (TOI) SEC filings — annual & quarterly reports (10-K, 10-Q)
TOI Frequently Asked Questions
The Oncology Institute, Inc. (TOI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
The Oncology Institute, Inc. (TOI) reported $545.8M in revenue for fiscal year 2025. This represents a 251% increase from $155.4M in 2019.
The Oncology Institute, Inc. (TOI) grew revenue by 27.8% over the past year. This is strong growth.
The Oncology Institute, Inc. (TOI) reported a net loss of $43.5M for fiscal year 2025.
Dividend & Returns
The Oncology Institute, Inc. (TOI) had negative free cash flow of $25.7M in fiscal year 2025, likely due to heavy capital investments.